Projects per year
Personal profile
Personal profile
Dr. Qing Yi is a trained medical immunologist with over 25 years of experience as a well-funded and published researcher. He is one of the leading investigators in the fields of tumor immunology and immunotherapy in multiple myeloma and other cancers.
Since arriving in the US in 1998, Dr. Yi has been awarded, as the PI, 9 R01s from NCI, 1 project and 1 core grant in the MDACC Myeloma SPORE (P50), 4 R01-type translational grants from the LLS, 4 Senior Researcher Awards from the MMRF, 2 K99/R00 grants (as the mentor), and numerous intramural and industry grants. Dr. Yi and colleagues have published more than 160 peer-reviewed research articles, with 45 being in top-tier journals with an impact factor of greater than 10.
Prior to his current appointment as Associate Director of the Houston Methodist Cancer Center, Dr. Yi had faculty appointments at Lerner Research Institute at the Cleveland Clinic in Ohio, MD Anderson Cancer Center, University of Arkansas for Medical Sciences, and Karolinska Hospital and Institute, Sweden.
Research interests
For the past two decades, Dr. Yi's laboratory has been working on the following research:
(1) characterizing myeloma- and tumor-specific T cells and their subsets and examining their functions in relationship to myeloma tumor cells using both in vitro and in vivo approaches
(2) identifying novel myeloma-associated antigens and better methods for immunotherapy
(3) investigating the cross-talk between the tumor microenvironment and the immune system in malignancy
(4) clinical trials to evaluate the efficacy of immunizing patients with idiotype or dendritic cell-based vaccines
(5) exploring immunotherapies using novel myeloma antigens such as DKK1 in multiple myeloma. Our recent research focuses on (a) developing novel therapeutic monoclonal antibodies for myeloma and other cancers, (b) identifying T-cell subsets that have potent anti-tumor effects after adoptive transfer, and (c) identifying tumor microenvironment components that induce tumor drug resistance.
A commentary written by Dr. Edgar Schmitt and Dr. Tobias Bopp in J Clin Invest (122:3857-3859) comments that “During the last two decades the laboratory of Qing Yi has significantly contributed to our current understanding of potential immunotherapies in human malignancies by describing the role of DCs – and particular T cells – in multiple myeloma.”
Education/Academic qualification
Molecular Medicine, Postdoctoral Fellowship, Karolinska Institute
1993 → 1995
Medical Sciences, PhD, Karolinska Institute
1990 → 1993
Medicine, MB MMed, Sun Yat-sen Univ. of Med. Sciences
1983 → 1986
Medicine, MD, Jiangxi Medical College, Jiangxi, P.R. China
1978 → 1983
External positions
Professor of Cancer Biology in Medicine, Weill Cornell Medical College
Oct 1 2019 → …Research Area Keywords
- Cancer
Free-text keywords
- Hematological malignancies
- Cancer biology
- Cancer immunotherapy
- Myeloma
Fingerprint Dive into the research topics where Qing Yi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 25 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
- 5 Active
Role of tumor microenvironment-derived cholesterol in CD8+ T-cell exhaustion
8/1/19 → 7/31/24
Project: Federal Funding Agencies
Targeting macrophages to sensitize myeloma to immune checkpoint blockade
3/1/19 → 2/28/22
Project: Federal Funding Agencies
Role of MIF in myeloma bone homing and drug response
1/1/19 → 12/31/21
Project: Federal Funding Agencies
A novel T-cell subset able to kill relapsed cancers
7/1/16 → 6/30/21
Project: Federal Funding Agencies
Research Output
Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma
Tseng, H. C., Xiong, W., Badeti, S., Yang, Y., Ma, M., Liu, T., Ramos, C. A., Dotti, G., Fritzky, L., Jiang, J. G., Yi, Q., Guarrera, J., Zong, W. X., Liu, C. & Liu, D., Dec 1 2020, In : Nature Communications. 11, 1, 4810.Research output: Contribution to journal › Article
Open Access
Enhanced lipid accumulation and metabolism are required for the differentiation and activation of tumor-associated macrophages
Su, P., Wang, Q., Bi, E., Ma, X., Liu, L., Yang, M., Qian, J. & Yi, Q., Apr 1 2020, In : Cancer research. 80, 7, p. 1438-1450 13 p.Research output: Contribution to journal › Article
3
Scopus
citations
Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma
Hu, Y., Liu, H., Fang, C., Li, C., Xhyliu, F., Dysert, H., Bodo, J., Habermehl, G., Russell, B. E., Li, W., Chappell, M., Jiang, X., Ondrejka, S. L., Hsi, E. D., Maciejewski, J. P., Yi, Q., Anderson, K. C., Munshi, N. C., Ao, G., Valent, J. N. & 2 others, , May 15 2020, In : Cancer research. 80, 10, p. 2031-2044 14 p.Research output: Contribution to journal › Article
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces peripheral blood abnormalities and plasma cell neoplasms resembling multiple myeloma in mice
Wang, L., Kumar, M., Deng, Q., Wang, X., Liu, M., Gong, Z., Zhang, S., Ma, X., Xu-Monette, Z. Y., Xiao, M., Yi, Q., Young, K. H., Ramos, K. S. & Li, Y., Jan 1 2019, In : Cancer Letters. 440-441, p. 135-144 10 p.Research output: Contribution to journal › Article
6
Scopus
citations
CCL2 promotes macrophages-associated chemoresistance via MCPIP1 dual catalytic activities in multiple myeloma
Xu, R., Li, Y., Yan, H., Zhang, E., Huang, X., Chen, Q., Chen, J., Qu, J., Liu, Y., He, J., Yi, Q. & Cai, Z., Oct 14 2019, In : Cell death & disease. 10, 10, p. 781Research output: Contribution to journal › Article
3
Scopus
citations